41.99 +0.01 (0.02%)
After hours: 7:14PM EDT
|Bid||41.86 x 1200|
|Ask||42.17 x 1100|
|Day's range||41.26 - 42.33|
|52-week range||36.65 - 64.50|
|Beta (5Y monthly)||0.56|
|PE ratio (TTM)||10.80|
|Forward dividend & yield||1.83 (4.48%)|
|Ex-dividend date||19 May 2020|
|1y target est||N/A|
Walgreens (WBA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Nasdaq and the S&P 500 closed higher on Wednesday as investors focused on signs of economic recovery and better than expected economic data.
Walgreens Boots Alliance (NASDAQ: WBA) is a household-name dividend stock that has had its share of ups and downs this year. The pharmacy stock is currently trading 16% above its lowest price over the trailing 12 months, and roughly 34% below its 52-week high. Here's what you need to know before you scoop up Walgreens stock.
To honor the service and sacrifices of Americans who served in the armed forces, Walgreens is offering a weekend Independence Day percent discount to all veterans, active duty military personnel and their immediate family members.
(Bloomberg Opinion) -- The colossal buyout of Walgreens Boots Alliance Inc. mooted last year may now look like a fantasy. But the pandemic will create opportunities for Chief Executive Officer Stefano Pessina to do preparatory dealmaking that would make it easier to take the drugstore group private. One option for the Italian billionaire could be to remove the company’s middle name by selling the historic Boots business in the U.K.Attention has recently focused on whether the owner of Walgreens and Duane Reade pharmacies could offload its pharmaceuticals wholesale arm. Drug distribution company AmerisourceBergen Corp. approached it about buying the unit for $6 billion, Reuters reported in May. Coincidentally, Walgreens has a 28% stake in AmerisourceBergen that could be worth a similar amount.But Pessina is unlikely to want to part with the division, which mainly operates under the Alliance Healthcare brand. It’s where he began building his empire more than four decades ago. Whereas Boots, the British high-street retailer that began life selling herbal remedies in Nottingham in 1849, didn’t become part of his company until 2006. That makes the chain, with about 2,500 stores in the U.K., a plausible alternative.True, Boots’s sales and profits have declined over the past three years as it grappled with online competition. But it was one of the few retailers allowed to continue operating in Britain during the pandemic. With the Covid-19 crisis expected to spark a surge in spending on health, a buyer might see some turnaround potential in the asset now.That may help Pessina get a decent valuation for the division, which generates two-thirds of its sales from non-prescription health-care and beauty products. According to the most recent accounts available, Boots U.K. had 6.7 billion pounds ($8.3 billion) of revenue in the year to August 2019. Ebitda fell from 572 million pounds in 2018 to 391 million pounds in 2019, hurt by a 70 million-pound increase in costs from a plan to close 200 stores.Given Boots is a largely defensive brick-and-mortar retailer, a useful valuation benchmark would be the U.K. supermarkets, which are valued at between five and eight times their estimated yearly Ebitda. The extent of Boots’s exposure to higher-margin beauty and personal-care items argues for a top-end valuation. That would imply an enterprise value of about 4.2 billion pounds ($5.2 billion), assuming the business can generate annual Ebitda of about 500 million pounds, with another 30 million pounds from its optician services.Boots also operates stores in Ireland, Norway, the Netherlands and Thailand, and it owns 49% of a hearing-care joint venture with Sonova Holding AG. So depending what is included, the exit price may be higher. The question is who might want to buy Boots. A.S. Watson Holdings Ltd., owner of the British Superdrug chain, would be the obvious acquirer, but a combination of the two would likely be prohibited on competition grounds. The same goes for the U.K. supermarkets, even though Tesco Plc has the scale and its incoming CEO Ken Murphy has been a Walgreens lifer.Maybe private equity would be interested in a second go. In 2007, a year after merging his Alliance Unichem chain with Boots, Pessina took the group private with KKR in a $14 billion deal, then Europe’s biggest-ever buyout. This time, an acquirer would need to believe in the opportunity to tap into demand from consumers prioritizing their health and be willing to invest in modernizing Boots’s stores and reinforcing its online offering.Of course, a sale of Boots would be small compared to a transaction encompassing Walgreens as a whole. But it may be the best deal available to Pessina right now, one that could set the stage for even bigger things another day.This column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Andrea Felsted is a Bloomberg Opinion columnist covering the consumer and retail industries. She previously worked at the Financial Times.For more articles like this, please visit us at bloomberg.com/opinionSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Walgreens' (WBA) tie-ups with Alphabet's life sciences and healthcare segment, Verily on multiple projects related to chronic ailments buoy optimism.
Shares in Walgreens Boots Alliance Inc (NSQ:WBA) are currently trading at 40.75 but a key question for investors is how the economic uncertainty caused by Covi...
There is great comfort to be found in regular, reliable dividend payouts – especially in times of economic uncertainty. But finding shares that can pay them is...
Contrarian value investors are always on the look-out for shares that the market has overlooked. In times of economic uncertainty - when stock prices become er...
Walgreens Boots Alliance (WBA) closed the most recent trading day at $43.55, moving +0.58% from the previous trading session.
In the latest trading session, Walgreens Boots Alliance (WBA) closed at $42.97, marking a +1.92% move from the previous day.
Warren Buffett isn't going to invest in every good value stock that's available on the markets -- there are just too many of them out there. With a good mix of value, stability, and moat, the three stocks listed below could appeal to investors who want to invest like the Oracle of Omaha. Walgreens Boots Alliance (NASDAQ: WBA) is a household name and the pharmacy retailer provides many day-to-day essentials for customers.
CVS Health (NYSE: CVS) and Walgreens Boots Alliance (NASDAQ: WBA) have both rolled out drive-through COVID-19 testing. Consumers probably won't keep on stocking up and filling prescriptions early as much with states relaxing their stay-at-home restrictions.
Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Walgreens...
There is great comfort to be found in regular, reliable dividend payouts, especially in times of economic uncertainty. But finding shares that can pay them isn8230;
The eventual stabilization in the business, a high dividend yield, and strong financial resources more than offset the near-term impact of COVID-19 on this pharmacy business.
The company, which has a health insurance business, a large pharmacy benefit manager and retail pharmacy stores, said it still expects 2020 adjusted profit of $7.04 to $7.17 per share, and its shares rose 2.3% to $62.62. "Sticking with the guidance should be enough for the stock at a time when the company is also dedicating extra resources to manage the COVID-19 pandemic," said Bank of America analyst Michael Cherny.
In the latest trading session, Walgreens Boots Alliance (WBA) closed at $42.02, marking a -1.01% move from the previous day.
(Bloomberg) -- In mid-March, Pete Massaro felt like he was in over his head. The global coronavirus pandemic was spreading quickly through the U.S., and Massaro, an engineer at Verily, the life sciences unit owned by Alphabet Inc., had suddenly been tasked with heading up the company’s efforts to help speed testing people for Covid-19, the disease caused by the virus. He now had three days to open two drive-through testing sites.It was a tall order. Massaro’s team would have to find suitable locations, staff them, source supplies and figure out how to safely do the tests. Then, adding to the stress, President Donald Trump announced out of the blue that Google, Verily’s sister unit under the Alphabet umbrella, was working on a nationwide system to coordinate testing. While Trump mistook Verily for Google, he also overpromised on the effort behind the fledgling operation, which was to start with only two counties in California. The announcement on March 13 threw Massaro’s team abruptly into the spotlight. After a sleepless weekend, Verily’s project went live on Monday March 16. “This didn’t feel as serious until it became very serious,” said Massaro, who is director of automation at Verily. “It sort of shook us into action.”In the nearly two months since Trump’s announcement, the pressure hasn't let up. Verily, along with local health officials, private clinics and large corporations, have scrambled to quickly open thousands of pop-up testing sites across the country in an effort to fill gaps in the American health-care system. But it’s not clear that this patchwork model of testing sites will ever reach the level of testing necessary, or the right people, to ease up on national social distancing requirements and help businesses safely reopen. As of May 4, Verily had facilitated testing for about 42,000 people. That’s a fraction of the nearly 7 million tests done across the U.S. since early January, according to The COVID Tracking Project. But that isn’t nearly up to the 500,000 tests a day experts say the U.S. will need -- at a minimum. Right now, the country is doing about half of that on the most active days. Testing is still limited to people who are ill or part of high-risk populations such as health care workers and nursing home residents. But it will need to expand to include everyone who comes into contact with a person who is positive.Even for a company like Verily, backed by Alphabet with its immense financial and human resources, getting a testing program up and running is extremely complicated. Verily is, at its core, a technology and research company, not a medical facility. Its initial proposal for Covid-19 testing was to create a website to help screen people with symptoms and send them to one of two Verily sites where they could be tested. On its first day in operation, Verily’s website was overwhelmed with applicants. The company tested just 20 people.Since then, it’s moved toward coordinating testing, rather than conducting its own tests or processing the results. Partnering with drugstore chain Rite Aid Corp. and the California Department of Health, Verily is now involved with 37 locations in nine states. Those sites can each do about 250 tests a day. Verily is also looking at mobile and walk-in testing sites to help serve people who don’t have cars or live far from a permanent site. “By scaling to more states and more individual sites, we aim to not only help individuals who need to be tested for Covid-19 but also play a supportive role in driving evidence-driven policy that will successfully manage this health crisis,” a Verily spokesperson said in an email.The U.S. government is pushing for more testing efforts as it seeks to reopen the economy as soon as possible while hoping to avert a second wave of infection. Last week the White House announced that it’s expanding efforts with Rite Aid, Walmart Inc., CVS Health Corp. and Walgreens Boots Alliance Inc. to open parking-lot testing facilities nationwide. The administration is helping determine the locations and is offering funding assistance. As the U.S. moves toward creating more long-term testing solutions, CVS Chief Medical Officer Troyen Brennan has said the company expects small, nimble testing sites in vans or kiosks will become more common, rather than places like a shuttered casino and college where the company opened its first testing sites. CVS is planning to expand its operations to offer testing at 1,000 locations, including in its store parking lots and drive-through windows, and eventually hopes to process 1.5 million tests a month.“This is the blunt part of the pandemic response where we put up big tents and try to keep people socially isolated,” he said in an interview last month. The next step is moving past the emergency phases and designing a system that works smoothly all over the country, Brennan said.Finding locations for testing sites can be difficult, especially with social distancing efforts enforced.“We got chased out of a lot of spots,” Massaro said. Local officials had seen news footage of huge crowds of potentially sick people queueing up for tests elsewhere and didn’t want that in their community, he said.Getting enough equipment to do the tests is also still a problem.“Every day is a struggle to match the amount of PPE and swabs you need,” Massaro said, referring to personal protective equipment for health care workers. “That’s the way the world is right now, getting those supplies in place has taken a lot of work.”Diagnostic testing is just one part of a multipronged effort to get people back to work, eating in restaurants and going to school. Widespread contact tracing, or tracking the disease as it spreads from person to person, will need to be in place to contain new outbreaks, as will antibody tests that help public health officials judge how much a disease has spread within a community and who might be potentially immune to infection. Disagreements between President Trump and state governments over the best approach suggest it’s unlikely a truly coordinated national effort to stop the disease will come together.Still, the private efforts are pushing forward, ramping up testing as best they can on their own. Verily, for instance, has rapidly diverted company resources toward its own testing efforts, sometimes setting up sites virtually overnight.“Scaling the test sites is absolutely doable,” Massaro said. “There’s a lot of innovation happening.”For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Walgreens owns about 27% of AmerisourceBergen and is its biggest customer. The two companies have explored various possibilities for combining operations in recent years, including a sale of AmerisourceBergen to Walgreens, on the theory that their drug distribution businesses would be better positioned to withstand competitive price pressures through even bigger scale. The coronavirus pandemic has weighed on Walgreens' retail business since then, however.